Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTI Bags Cash, Turns Its Back On Zevalin

This article was originally published in The Pink Sheet Daily

Executive Summary

Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.

You may also be interested in...



Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.

Cancer Drug Zevalin May Finally Thrive Under Spectrum

The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.

Cancer Drug Zevalin May Finally Thrive Under Spectrum

The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel